Production (Stage)
Apellis Pharmaceuticals, Inc.
APLS
$17.44
-$0.34-1.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -223.68M | -197.88M | -250.10M | -332.89M | -417.27M |
| Total Depreciation and Amortization | 1.80M | 1.80M | 1.83M | 1.83M | 1.81M |
| Total Amortization of Deferred Charges | 2.07M | 1.56M | 1.05M | 464.00K | 300.00K |
| Total Other Non-Cash Items | 115.97M | 125.01M | 131.39M | 132.09M | 133.00M |
| Change in Net Operating Assets | 95.54M | -18.36M | -89.26M | -209.77M | -267.93M |
| Cash from Operations | -8.29M | -87.87M | -205.10M | -408.28M | -550.10M |
| Capital Expenditure | -118.00K | -403.00K | -478.00K | -525.00K | -807.00K |
| Sale of Property, Plant, and Equipment | -- | -- | 99.00K | 99.00K | 99.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -118.00K | -403.00K | -379.00K | -426.00K | -708.00K |
| Total Debt Issued | 365.45M | 365.45M | 365.45M | 365.45M | -- |
| Total Debt Repaid | 0.00 | 0.00 | 0.00 | -1.59M | -- |
| Issuance of Common Stock | 9.63M | 18.83M | 44.28M | 47.48M | 68.41M |
| Repurchase of Common Stock | -36.00K | -57.00K | -44.00K | -41.00K | -69.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -333.75M | -234.98M | -260.36M | -258.77M | 43.26M |
| Cash from Financing | 41.30M | 149.24M | 149.33M | 152.53M | 111.61M |
| Foreign Exchange rate Adjustments | -91.00K | -659.00K | 890.00K | 259.00K | -130.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 32.80M | 60.31M | -55.26M | -255.92M | -439.33M |